ROIVANT SCIENCES LTD

Roivant Sciences (ROIV) sees a 1.77 % jump, trading at $37.45 with a $26.6 bn market cap, above its 200‑day SMA and poised for upside if it hits clinical milestones.

Roivant Sciences’ stock jumps 5.4% as Priovant’s Phase 3 trials show breakthrough benefits for brepocitinib in uveitis – a pivotal moment for investors in biotech and ophthalmology.

Roivant Sciences rises 0.63% as its Phase‑3 brepocitinib study delivers steroid‑free uveitis success, hinting at a 2027 sNDA launch amid active insider trades.